Abbott Laboratories
This article was originally published in The Gray Sheet
Executive Summary
Signs a new five-year, "multimillion-dollar" contract with Voluntary Hospitals of America (VHA) that expands on an existing agreement, Abbott announces Jan. 19. Financial terms of the deal were not disclosed. Abbott said the contract, under which it will supply VHA's 950 health care organizations with more than 600 intravenous products, including the LifeShield needle-stick protection system, "combines the traditional benefits of preferred pricing with new incentives based on effective utilization of I.V. products"
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.